SpineThera Announces Results for SX600 from its SALIENT Phase 2 Sciatica Pain Clinical Trial Support
PLYMOUTH, Minn.--(BUSINESS WIRE)--SpineThera, Inc., a privately held, clinical-stage pharmaceutical company focused on the development of SX600 (a novel formulation of extended-release dexamethasone microspheres for transforaminal epidural injection [TF-EI] for the management of sciatica pain) today announced promis...
Source: pharmiweb.com